

## Interim Report, January - September 2012

Stockholm, 30 October 2012

Geoffrey McDonough, CEO: "The third quarter continued to demonstrate solid underlying growth in product sales and an improvement of the gross margin in line with our expectations. In September we reported positive top-line results from our factor IX phase III program with Biogen Idec for the development of a long-lasting recombinant coagulation factor for hemophilia B. In addition we were granted priority review by the FDA for our application for Kineret® for the NOMID indication with an expected approval date in late December 2012. We also continued to strengthen the Partner Product portfolio through the extension and expansion of several existing partnerships."

### Third quarter

- Total revenues were SEK 463.8 M (447.1). Revenues for the previous year include co-promotion for ReFacto AF®/BeneFIX® and discontinued products in the amount of SEK 29.9 M. Adjusted for these items and for currency effects, total revenues increased by 12%.
- Product revenues<sup>1)</sup> amounted to SEK 306.4 M (328.3), showing an increase of 5% adjusted as above.
- Revenues from ReFacto manufacturing and royalty rose by 33% to SEK 157.4 M (118.6).
- Gross margin improved to 57.5% (52.3) driven by higher plant utilization compared to the previous year when the facility in Stockholm was closed for scheduled maintenance in July and August, and by efficiency gains in production.
- Operating expenses were unchanged at SEK 227.1 M (227.7).
- The previously published outlook for 2012 remains unchanged.

Amounts in SEK million	Q3			Jan- Sep			Full year	
	2012	2011	Change	2012	2011	Change	2011	
Total revenues	463.8	447.1	4%	1,451.3	1,474.5	-2%	1,910.8	
Gross profit	266.6	233.9	14%	773.0	794.3	-3%	974.6	
Gross margin	57%	52%	10%	53%	54%	-1%	51%	
Operating profit/loss before amortizations and non-recurring items	29.8	3.0	>100%	366.5	243.2	51%	127.3	
Operating profit/loss	-34.7	-54.4	36%	138.2	9.1	>100%	-318.6	
Profit/loss for the period	-45.4	-38.4	-18%	41.8	6.1	>100%	17.9	
Earnings/loss per share, SEK <sup>2)</sup>	-0.17	-0.14	-18%	0.16	0.03	>100%	0.07	

<sup>1)</sup> Product revenues include Core Products and Partner Products.

<sup>2)</sup> Comparative figures have been adjusted to reflect the rights issue in June 2011.

## Revenues

Total revenues for the third quarter of 2012 were SEK 463.8 M (447.1). The figure for the previous year includes discontinued products and co-promotion for ReFacto AF®/BeneFIX® in a total amount of SEK 29.9 M. The co-promotion rights were divested as of February 2012.

### Revenues by Business Area

Amounts in SEK million	Q3		Change		Jan - Sep		Change		Full year
	2012	2011	%	% at CER	2012	2011	%	% at CER	2011
<b>Core Products</b>									
Kineret	114.4	102.5	12%	12%	353.9	312.6	13%	11%	422.0
Orfadin	82.6	80.2	3%	6%	265.4	241.4	10%	10%	315.7
Other core products	17.7	19.0	-7%	-1%	62.2	54.9	13%	15%	74.6
<b>Total</b>	<b>214.7</b>	<b>201.7</b>	<b>6%</b>	<b>9%</b>	<b>681.5</b>	<b>608.9</b>	<b>12%</b>	<b>11%</b>	<b>812.3</b>
<b>Partner Products</b>									
Current portfolio	91.7	96.7	-5%	-3%	294.7	272.9	8%	8%	373.6
Discontinued products	0.0	5.4	-100%	-100%	0.0	45.0	-100%	-100%	45.0
Co-promotion revenues	0.0	24.5	-100%	-100%	12.0	79.0	-85%	-85%	105.0
<b>Total</b>	<b>91.7</b>	<b>126.6</b>	<b>-28%</b>	<b>-26%</b>	<b>306.7</b>	<b>396.9</b>	<b>-23%</b>	<b>-23%</b>	<b>523.6</b>
<b>ReFacto</b>									
Manufacturing revenues	118.9	98.9	20%	20%	343.3	373.9	-8%	-8%	451.7
Royalty revenues	38.5	19.7	95%	86%	106.6	95.0	12%	6%	123.3
<b>Total</b>	<b>157.4</b>	<b>118.6</b>	<b>33%</b>	<b>31%</b>	<b>449.9</b>	<b>468.9</b>	<b>-4%</b>	<b>-5%</b>	<b>575.0</b>
Other revenues	-	0.1	-100%	-100%	13.1	0.0	n/a	n/a	-
<b>Total revenues</b>	<b>463.8</b>	<b>447.1</b>	<b>4%</b>	<b>5%</b>	<b>1,451.3</b>	<b>1,474.5</b>	<b>-2%</b>	<b>-2%</b>	<b>1,910.8</b>
Total revenues excl co-promotion and discontinued products	463.8	417.2	11%	12%	1,439.3	1,350.5	7%	6%	1,760.8

### Core Products

#### Kineret®

Sales of Kineret in the third quarter of 2012 increased by 12% to SEK 114.4 M (102.5) as a result of growth in both Europe and North America. Sales for the first nine months rose by 13% compared with the corresponding period in 2011.

#### Orfadin®

Sales of Orfadin in the quarter increased by 3% to SEK 82.6 M (80.2). Sales were driven by growth in North America and in Central and Eastern Europe, partially offset by negative currency effects (mainly EUR). Sales for the first nine months increased by 10% compared with the corresponding period in 2011.

### Partner Products

Revenues for Partner Products were SEK 91.7 M (126.6). Revenues for the previous year include co-promotion for ReFacto AF®/BeneFIX® and discontinued products in the amount of SEK 29.9 M. Adjusted for these items and for currency effects, total revenues decreased by 5%. Adjusted revenues for the first nine months rose by 8% compared with the first nine months in 2011.

Sales of Kepivance® were unchanged at SEK 20.2 M (20.0). Sales for the first nine months increased by 7% compared with the corresponding period in 2011.

Sales of Yondelis® declined by 3% to SEK 14.1 M (14.6). Sales for the first nine months increased by 8%.

The Partner Product portfolio was extended during the period with new agreements for Promixin® in the Nordic countries, Germany and Central and Eastern Europe, for Buronil® in the Baltic States, Austria, the Czech Republic and Portugal, and for a new product based on Netupitant-Palonosetron in the Nordic countries. Effective 1 January 2013 Sobi expects to return the rights for Willfact® in Germany to LFB but will retain the rights for the Nordic markets.

## ReFacto Manufacturing and Royalties

Total ReFacto manufacturing and royalty revenues in the quarter amounted to SEK 157.4 M (118.6).

Manufacturing revenues increase by 20% to SEK 118.9 M (98.9). Manufacturing revenues for the nine months period declined by 8% to SEK 343.3 M (373.9). The figure for 2011 includes the delivery of validation batches in the amount of SEK 42 M.

Royalties increased to SEK 38.5 M (19.7), mainly due to a difference in timing between quarters as compared to the previous year. Royalties for the nine months increased to SEK 106.6 M (95.0).

## Revenues by Region<sup>1)</sup>

Amounts in SEK million	Q3		Change		Jan - Sep		Change		Full year
	2012	2011	Change	% at CER	2012	2011	Change	% at CER	2011
Nordic <sup>2)</sup>	64.6	96.9	-33%	-30%	225.7	325.7	-31%	-30%	427.9
Europe	140.5	142.5	-1%	5%	460.7	413.3	11%	14%	540.9
North America	94.6	86.2	10%	4%	281.5	249.9	13%	6%	328.2
RoW	6.7	2.7	>100%	156%	20.2	16.8	20%	18%	38.9
<b>Total revenues</b>	<b>306.4</b>	<b>328.3</b>	<b>-7%</b>	<b>-5%</b>	<b>988.1</b>	<b>1,005.7</b>	<b>-2%</b>	<b>-2%</b>	<b>1,335.9</b>

<sup>1)</sup> Excluding ReFacto manufacturing and royalty revenues, including discontinued products.

<sup>2)</sup> Revenues in the Nordic region include co-promotion for ReFacto AF®/BeneFIX® and discontinued products.

## Gross profit

Gross profit increased to SEK 266.6 M (233.9), corresponding to a gross margin of 57.5% (52.3). Gross profit for the previous year includes co-promotion revenues of SEK 24.5 M.

The improvement in gross margin is a result of higher utilization of the plant in Stockholm, which was closed for scheduled maintenance in July and August of 2011, and of efficiency improvements following the scale-up of the downstream production process.

Gross profit for the nine months amounted to SEK 773.0 M (794.3) and includes one-time costs of SEK 64 M related to the transfer of Kineret production, a milestone payment received for Orfadin in the amount of SEK 13.1 M and co-promotion revenues of SEK 12.0 M. Gross profit for the previous year include costs for the transfer of Kineret production of SEK 31 M and co-promotion of SEK 79.0 M.

## Operating profit

Operating profit before amortization of intangible assets and non-recurring items (EBITA before non-recurring items) was SEK 29.8 M (3.3).

Operating expenses<sup>3)</sup> were SEK 227.0 M (227.7). Sales and administration expenses were unchanged from the previous year. Increased investment in the phase III program for Kiobrina was offset by savings within R&D from the restructuring measures implemented in 2011.

Amortization of intangible assets amounted to SEK 64.5 M (57.7). Other operating revenues and expenses amounted to SEK -9.7 M (-3.2).

Operating profit (EBIT) was SEK -34.7 M (-54.4).

## Net financial items and tax

Net financial items in the third quarter amounted to SEK -14.9 M (5.4). The financial net for the previous year was positively impacted by currency effects.

The tax for the third quarter was SEK 4.2 M (10.6). The tax rate in the quarter is relative high due to transaction related none deductible expenses.

<sup>3)</sup> Excluding amortization of intangible assets, non-recurring items, and other operating revenues and expenses.

### **Profit for the period**

Profit for the period was SEK -45.4 (-38.4). Earnings per share amounted to SEK -0.17 (-0.14).

### **Cash flow and investments**

Cash flow from operations before changes in working capital in the third quarter of 2012 was SEK 19.6 M (13.8). Non-cash items amounted to SEK 65.0 M (52.2) and were mainly due to amortization of product rights and licenses.

Working capital impacted cash flow by SEK -46.0 M (-13.7). Inventories declined, mainly for ReFacto and Kineret, offset by a reduction of current liabilities, mainly trade payables, which had a negative impact on working capital.

Cash flow from investing activities amounted to SEK -4.6 M (-28.7).

### **Financial position**

Cash and cash equivalents and short-term investments as of 30 September 2012 amounted to SEK 319.2 M compared with SEK 219.0 M as of 31 December 2011.

Net debt as of 30 September 2012 amounted to SEK 280.8 M compared with SEK 481.0 M as of 31 December 2011.

### **Equity**

Consolidated shareholders' equity as of 30 September 2012 amounted to SEK 4,986.4 M compared with SEK 4,963.4 M as of 31 December 2011.

### **Outlook for 2012**

The outlook was first published on 23 February 2012 and has not been changed:

Market conditions are expected to continue to be challenging, particularly in Europe due to the uncertain macroeconomic environment, and in the US related to the evolution of the new healthcare regime. The outlook is based on the assumption that the current SEK/USD and SEK/EUR exchange rates prevail during the year, and that market conditions do not significantly deteriorate.

Total revenues for the full year 2012 are expected to be approximately SEK 100 M lower than in 2011 reflecting the divestment of the ReFacto co-promotion rights.

Revenues for Core Products and Partner Products are expected to show mid to high single digit growth, while revenues for ReFacto manufacturing and royalty are expected to show low single digit growth. Revenues in 2011 from validation batches (SEK 42 M) and discontinued products (SEK 45 M) will not recur in 2012.

The gross margin for the full year 2012 is expected to be in line with the 2011 margin, which was 54% after adjustment for both the balance sheet write-downs and the divestment of co-promotion rights. Costs in 2012 related to the transfer of Kineret production are estimated at SEK 60 M and are expected to impact the gross margin primarily in the first half of the year. As a result of the renegotiated ReFacto manufacturing agreement with Pfizer, reduced quarterly variations in the ReFacto manufacturing gross margin are expected.

Operating expenses, excluding amortizations, are estimated at or below SEK 950 M.

The earlier reported milestone payment to Amgen of USD 55 M is now estimated to become due in Q4 2012 or in Q1 2013, with the ultimate timing dependent on the cumulative sales of Kineret.

## Research and Development

### Positive top-line results from rFIXFc phase III study

On September 26, Sobi and Biogen Idec announced positive top-line results from B-LONG, a global, multi-center, Phase III clinical study of the companies' long-lasting recombinant Factor IX Fc fusion protein (rFIXFc) for people with hemophilia B. Hemophilia B is a rare inherited disorder that impairs blood coagulation.

The top-line results showed that rFIXFc was effective in the control and prevention of bleeding, routine prophylaxis, and perioperative management, and was generally well-tolerated.

- Prophylactic regimens resulted in low single-digit annualized bleeding rates.
- Median dosing interval was 14 days in the individualized interval prophylaxis arm during the last 6 months on study.
- Greater than 90% of bleeding episodes were controlled by a single injection of rFIXFc.
- No patients developed inhibitors to rFIXFc.
- The primary efficacy and safety objectives were met and Biogen Idec plans to submit a BLA to US FDA in first half 2013.

Additional analyses of the B-LONG study are ongoing and the companies anticipate presenting further results at a future scientific meeting.

For a summary of key data from B-LONG, see the press release dated September 26 at [www.sobi.com](http://www.sobi.com) or at [www.biogenidec.com](http://www.biogenidec.com).

### Application for NOMID granted priority review

Sobi's application for Kineret for the indication of neonatal-onset multisystem inflammatory disease (NOMID) in the US has been granted priority review by the FDA (Food and Drug Administration) with an expected approval date of 25 December 2012. Priority review is granted to a pharmaceutical product that, if approved, would meet an unmet medical need.

### Development pipeline

Indication	Product/Project	Partner	Phase I	Phase II	Phase III	Reg phase
Hemophilia A	rFVIII Fc	Biogen Idec				
Hemophilia B	rFIX Fc	Biogen Idec				
Prevent growth restriction in premature infants	Kiobrina®					
Diuresis and seizures in neonates	Reformulated Bumetanide	Only For Children Pharmaceuticals (O4CP)				

### Life cycle management

Indication	Product/Project
CAPS	Kineret®
Hereditary tyrosinemia type 1	Orfadin®, liquid formulation

### Key dates

Activity	Expected timing
rFVIII Fc (hemophilia A): report phase III data	H2 2012
rFIX Fc (hemophilia B): phase III data	Reported, Sept 2012
Kiobrina® (prevent growth restriction): phase III data	2013

### **Personnel**

As of 30 September 2012, the number of full-time employees was 483 (497). The employees of the US subsidiary Sobi Inc. were included as of July 2012.

### **Other Information**

#### **Nomination Committee for AGM 2013**

In accordance with the decision by the Annual General Meeting on 26 April 2012 Swedish Orphan Biovitrum AB shall have a Nomination Committee consisting of four members, three of whom shall be representatives of the three largest shareholders as per August 31, and the Chairman of the Board of Directors.

The nomination committee for the 2013 Annual General Meeting consists of:

- Petra Hedengran, Investor AB
- Roger Johanson, Skandia Liv
- Åsa Nisell, Swedbank Robur Fonder
- Bo Jesper Hansen, Chairman of the Board of Swedish Orphan Biovitrum

The Nomination Committee will prepare proposals for the AGM 2013, including proposals for Chairman, Board members and if applicable auditors, as well as proposals for allocation of remuneration among these persons.

The Annual General Meeting 2013 will be held on April 26 at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm.

#### **Changes in Executive Management**

Wills Hughes-Wilson has moved into a newly created role of Vice President, Chief Patient Access Officer, where she will be responsible for Government Affairs, Communications, Patient Access Programs and Corporate Social Responsibility.

Jörgen Winroth has joined Sobi to lead the company's Investor Relations activities, reporting to the CFO. Jörgen has served as Director, Investor Relations for AstraZeneca North America for the past sixteen years. He has also served as consultant providing Investor Relations services to a number of Scandinavian corporations.

Åsa Stenqvist, who has served as interim VP, Head of Communications and Investor Relations, will leave Sobi on November 16, 2012.

#### **New subsidiary in Dubai**

A new subsidiary, Sobi Middle East FZ, has been established in Dubai. The new subsidiary will be the regional office for Middle East and support the company's expansion in this region.

Solna, 30 October 2012

Geoffrey McDonough  
President and CEO

#### **Forward-looking statement**

*This interim report includes forward-looking statements. Actual results may differ from those stated. Internal factors such as the successful management of research programs and intellectual property rights may affect future results. There are also external conditions such as the economic climate, political changes and competing research programs that may affect Swedish Orphan Biovitrum's results.*

## **Report of Review of Interim Financial Information**

### **Introduction**

We have reviewed this report for the period 1 January 2012 to 30 September 2012 for Swedish Orphan Biovitrum AB (publ). The board of directors and the CEO are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

### **Scope of Review**

We conducted our review in accordance with the Swedish Standard on Review Engagements SÖG 2410, Review of Interim Report Performed by the Independent Auditor of the Entity. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing, ISA, and other generally accepted auditing standards in Sweden. The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### **Conclusion**

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, in accordance with IAS 34 and the Swedish Annual Accounts Act, regarding the Group, and with the Swedish Annual Accounts Act, regarding the Parent Company.

Stockholm, 30 October 2012

PricewaterhouseCoopers AB

Mikael Winkvist  
Authorized Public Accountant

## Financial statements & Notes

### Statement of Comprehensive Income

Amounts in SEK million	Q3		Jan - Sep		Full year
	2012	2011	2012	2011	2011
Total revenues	463.8	447.1	1,451.3	1,474.5	1,910.8
Total cost of goods and services sold	-197.2	-213.1	-678.3	-680.1	-936.3
<b>Gross profit</b>	<b>266.6</b>	<b>233.9</b>	<b>773.0</b>	<b>794.3</b>	<b>974.6</b>
Sales and administration expenses <sup>1)</sup>	-194.5	-188.2	-603.8	-538.3	-804.4
Research and development expenses <sup>2)</sup>	-97.1	-97.3	-303.0	-324.4	-555.7
Non-recurring items <sup>3)</sup>	0.0	0.3	-34.0	-69.8	-80.4
Other operating revenues/expenses	-9.7	-3.2	306.0	147.2	147.4
<b>Operating profit/loss</b>	<b>-34.7</b>	<b>-54.4</b>	<b>138.2</b>	<b>9.1</b>	<b>-318.6</b>
Financial income/expenses	-14.9	5.4	-33.7	-33.2	-52.2
<b>Profit/loss after financial items</b>	<b>-49.6</b>	<b>-49.0</b>	<b>104.5</b>	<b>-24.1</b>	<b>-370.8</b>
Income tax expense	4.2	10.6	-62.7	30.2	388.8
<b>Profit/loss for the period</b>	<b>-45.4</b>	<b>-38.4</b>	<b>41.8</b>	<b>6.1</b>	<b>17.9</b>
<b>Other comprehensive income</b>					
Translation difference	0.2	0.0	-0.1	0.0	-0.2
Cash flow hedge	-11.9	0.0	0.2	0.0	0.0
<b>Comprehensive income for the period</b>	<b>-57.1</b>	<b>-38.4</b>	<b>41.9</b>	<b>6.1</b>	<b>17.7</b>
Earnings/loss per share after tax (SEK)	-0.17	-0.14	0.16	0.03	0.07
Earnings/loss per share after dilution (SEK)	-0.17	-0.14	0.16	0.03	0.07
<sup>1)</sup> Amortization and write-down of intangible assets included in Sales & Adm expenses	-64.5	-57.7	-194.3	-164.2	-237.9
<sup>2)</sup> Amortization and write-down of intangible assets included in Research and Development expenses	-	-	-	-	-127.6
<sup>3)</sup> Amortization and write-down of intangible assets included in non-recurring items	-	-	-	-	-2.6

**Balance Sheet**

<i>Amounts in SEK million</i>	<b>Sep 2012</b>	<b>Jun 2012</b>	<b>Mar 2012</b>	<b>Dec 2011</b>	<b>Sep 2011</b>
<b>ASSETS</b>					
<b>Fixed assets</b>					
Intangible fixed assets <sup>1)</sup>	4,741.6	4,802.9	4,862.6	4,885.1	5,070.9
Tangible fixed assets	135.8	140.3	147.0	155.9	219.3
Financial fixed assets	7.3	7.6	7.7	11.4	22.7
<b>Total fixed assets</b>	<b>4,884.7</b>	<b>4,950.8</b>	<b>5,017.3</b>	<b>5,052.4</b>	<b>5,312.9</b>
<b>Current assets</b>					
Inventories	742.3	810.5	829.8	893.8	953.2
Accounts receivable	367.1	350.6	413.0	309.6	406.8
Current receivables, non-interest bearing <sup>2)</sup>	243.5	248.9	201.4	224.6	198.4
Cash and cash equivalents	319.2	350.0	314.1	219.0	73.1
<b>Total current assets</b>	<b>1,672.1</b>	<b>1,760.0</b>	<b>1,758.3</b>	<b>1,647.1</b>	<b>1,631.4</b>
<b>Total assets</b>	<b>6,556.8</b>	<b>6,710.8</b>	<b>6,775.6</b>	<b>6,699.5</b>	<b>6,944.3</b>
<b>EQUITY AND LIABILITIES</b>					
<b>Shareholders equity</b>	<b>4,986.4</b>	<b>5,040.4</b>	<b>5,094.5</b>	<b>4,963.4</b>	<b>4,948.3</b>
<b>Long-term liabilities</b>					
Long-term debt	600.0	600.0	492.5	700.7	686.1
Long-term liabilities, non-interest bearing <sup>3)</sup>	452.4	461.5	472.2	358.7	730.9
<b>Total long-term liabilities</b>	<b>1,052.4</b>	<b>1,061.5</b>	<b>964.7</b>	<b>1,059.4</b>	<b>1,417.0</b>
<b>Current liabilities</b>					
Short term debt	14.3	13.7	13.7	13.9	14.0
Current liabilities, non-interest bearing	503.7	595.2	702.7	662.8	565.0
<b>Total short-term liabilities</b>	<b>518.0</b>	<b>608.9</b>	<b>716.4</b>	<b>676.7</b>	<b>579.0</b>
<b>Total equity and liabilities</b>	<b>6,556.8</b>	<b>6,710.8</b>	<b>6,775.6</b>	<b>6,699.5</b>	<b>6,944.3</b>

<sup>1)</sup> Including goodwill SEK 1,605.3 M

<sup>2)</sup> June includes a foreign exchange hedge of SEK 12 M.

<sup>3)</sup> The Swedish government has proposed a reduction in the company tax rate from 26.3% to 22.0% as of 2013. If the reduction will take effect it will lead to a positive one-time effect related to a reduction of Sobi's deferred tax liability estimated at approximately SEK 70 M.

**Changes in Equity**

<i>Amounts in SEK million</i>	<b>Jan - Sep</b>		<b>Full year</b>
	<b>2012</b>	<b>2011</b>	<b>2011</b>
<b>Opening balance</b>	<b>4,963.4</b>	<b>4,342.4</b>	<b>4,342.4</b>
Change in accounting principle <sup>1)</sup>	-24.6	-	-
<b>Opening balance</b>	<b>4,938.8</b>	<b>4,342.4</b>	<b>4,342.4</b>
Sharebased compensation to employees	5.7	5.7	9.3
Issue of shares	-	594.0	594.0
Comprehensive income for the period	41.9	6.1	17.7
<b>Equity, end of period</b>	<b>4,986.4</b>	<b>4,948.3</b>	<b>4,963.4</b>

<sup>1)</sup> As a consequence of adopting new accounting principles, IAS 19, as from 1 January 2012, actuarial losses per 31 December 2011 have been charged to equity as an adjustment of opening balances.

**Cash Flow Statement**

<i>Amounts in SEK million</i>	Q3		Jan - Sep		Full year
	2012	2011	2012	2011	2011
Net result	-45.4	-38.4	41.8	6.1	17.9
Non-cash items <sup>1)</sup>	65.0	52.2	310.1	82.3	100.4
<b>Cash flow from operations before change in working capital</b>	<b>19.6</b>	<b>13.8</b>	<b>351.9</b>	<b>88.3</b>	<b>118.3</b>
Change in working capital	-46.0	-13.7	-103.6	-120.4	-15.4
<b>Cash flow from operations</b>	<b>-26.4</b>	<b>0.1</b>	<b>248.3</b>	<b>-32.1</b>	<b>102.9</b>
Acquisition of business, net of cash acquired	–	-25.4	–	-29.8	-29.8
Investment in intangible fixed assets	-2.7	-1.3	-43.7	-6.4	-7.6
Investment in tangible fixed assets	-1.9	-0.3	-4.4	-5.4	-7.7
Divestment of tangible fixed assets	–	–	–	1.0	1.3
Investment/Divestment of financial assets	–	-1.7	–	–	–
<b>Cash flow from investing activities</b>	<b>-4.6</b>	<b>-28.7</b>	<b>-48.1</b>	<b>-40.6</b>	<b>-43.7</b>
Loans - Raising/Amortization	–	-13.2	-100.0	-486.2	-472.4
Issue of shares	–	–	–	594.0	594.0
<b>Cash flow from financing activities</b>	<b>–</b>	<b>-13.2</b>	<b>-100.0</b>	<b>107.8</b>	<b>121.6</b>
<b>Net change in cash</b>	<b>-31.0</b>	<b>-41.9</b>	<b>100.2</b>	<b>35.1</b>	<b>180.8</b>
Liquid funds at the beginning of the period	350.0	115.0	219.1	38.5	38.5
Translation difference in cash flow and liquid funds	0.2	-0.1	-0.1	-0.5	-0.2
<b>Liquid funds at the end of the period</b>	<b>319.2</b>	<b>73.1</b>	<b>319.2</b>	<b>73.1</b>	<b>219.1</b>
Short-term investments	–	–	–	–	–
<b>Liquid funds and short-term investments at the end of the period</b>	<b>319.2</b>	<b>73.1</b>	<b>319.2</b>	<b>73.1</b>	<b>219.1</b>
<sup>1)</sup> Depreciations, amortization and deferred tax:					
Depreciation tangible fixed assets	8.1	10.0	24.9	36.6	81.8
Amortization intangible assets	64.5	57.7	194.3	164.2	368.1
Deferred tax	-12.4	-12.5	47.5	-34.1	-394.7

## Key Ratios and Other Information

Amounts in SEK million	Q3		Jan - Sep		Full year
	2012	2011	2012	2011	2011
<b>Return on</b>					
Shareholders' equity	-0.9%	-0.8%	0.8%	0.1%	0.4%
Total capital	-0.5%	-0.6%	2.1%	0.3%	-4.5%
<b>Profit numbers</b>					
Gross profit	266.6	233.9	773.0	794.3	974.6
EBITDA	37.9	13.3	357.4	209.9	131.3
Operating profit before amortizations and non-recurring items	29.8	3.0	366.5	243.1	127.3
Operating profit before non-recurring items	-34.7	-54.7	172.2	78.9	-238.2
EBITA	29.8	3.3	332.5	173.3	49.5
EBIT	-34.7	-54.4	138.2	9.1	-318.6
Profit	-45.4	-38.4	41.8	6.1	17.9
<b>Per share data (SEK)</b>					
Shareholders' equity per share	18.8	18.7	18.8	18.7	18.7
Shareholders' equity per share after dilution	18.8	18.6	18.8	18.6	18.7
Cash flow per share	-0.1	-0.2	0.4	0.1	0.7
Cash flow per share after dilution	-0.1	-0.2	0.4	0.1	0.7
<b>Other information</b>					
Gross margin	57.5%	52.3%	53.3%	53.9%	51.0%
Equity ratio	76.0%	71.1%	76.0%	71.3%	74.1%
Net debt	280.8	613.0	280.8	613.0	481.0
Number of ordinary shares	265,226,598	265,226,598	265,226,598	265,226,598	265,226,598
Number of C-shares	4,408,260	2,068,534	4,408,260	2,068,534	2,068,534
Average number of ordinary shares	265,226,598	265,226,598	265,226,598	234,332,072	242,119,185
Outstanding warrants	0	300,000	0	300,000	300,000
Number of shares after dilution	265,226,598	265,865,598	265,226,598	265,865,598	265,226,598
Average number of ordinary shares after dilution	265,226,598	265,865,598	265,226,598	235,002,433	242,119,185

*Return on shareholders' equity*

Profit/loss after tax as a percentage of average shareholders' equity.

*Return on total capital*

Profit/loss after financial items plus financial expenses as a percentage of average total assets.

*Gross profit*

Net sales less cost of goods and services sold.

*EBITDA*

Operating profit/loss before depreciation and amortization.

*EBITA*

Operating profit/loss before amortization.

*EBIT*

Operating profit/loss.

*Profit*

Net profit for the period.

*Shareholders' equity per share*

Shareholders' equity divided by the number of shares.

*Shareholders' equity per share after dilution*

Shareholders' equity divided by the number of shares after dilution.

*Cash flow per share*

Changes in cash and cash equivalents divided by the weighted average number of outstanding shares.

*Cash flow per share after dilution*

Changes in cash and cash equivalents divided by the weighted average number of shares after dilution.

*Gross margin*

Gross profit as a percentage of net sales.

*Equity ratio*

Shareholders' equity as a proportion of total assets.

*Net debt*

Long and short term liabilities to credit institutes less cash and cash equivalents.

*Non-recurring items*

Non-recurring items are defined as transactions of non-recurring nature

## Quarterly Trend Data

<i>Amounts in SEK million</i>	<b>Q1-11</b>	<b>Q2-11</b>	<b>Q3-11</b>	<b>Q4-11</b>	<b>Q1-12</b>	<b>Q2-12</b>	<b>Q3-12</b>
<b>Total Revenues</b>	<b>537.4</b>	<b>490.0</b>	<b>447.1</b>	<b>436.4</b>	<b>506.7</b>	<b>480.7</b>	<b>463.8</b>
COGS	-253.5	-213.5	-213.1	-256.1	-247.3	-233.8	-197.2
<b>Gross profit</b>	<b>283.9</b>	<b>276.4</b>	<b>233.9</b>	<b>180.3</b>	<b>259.4</b>	<b>246.9</b>	<b>266.6</b>
Gross margin	53%	56%	52%	41%	51%	51%	57%
Sales and administration expenses	-116.7	-126.9	-130.4	-192.5	-127.8	-151.8	-130.0
Research and development expenses	-102.4	-124.6	-97.3	-103.7	-97.4	-108.5	-97.1
<b>OPEX</b>	<b>-219.2</b>	<b>-251.5</b>	<b>-227.7</b>	<b>-296.2</b>	<b>-225.1</b>	<b>-260.3</b>	<b>-227.1</b>
<b>% of sales</b>	<b>-41%</b>	<b>-51%</b>	<b>-51%</b>	<b>-68%</b>	<b>-44%</b>	<b>-54%</b>	<b>-49%</b>
Other operating revenues/expenses	-5.0	155.4	-3.2	0.2	307.9	7.8	-9.7
<b>EBITA before non-recurring items</b>	<b>59.7</b>	<b>180.4</b>	<b>3.0</b>	<b>-115.7</b>	<b>342.2</b>	<b>-5.6</b>	<b>29.8</b>
<b>% of sales</b>	<b>11%</b>	<b>37%</b>	<b>1%</b>	<b>-27%</b>	<b>68%</b>	<b>-1%</b>	<b>6%</b>
Non-recurring items	-70.1	0.0	0.3	-8.0	-34.0	0.0	0.0
<b>EBITA</b>	<b>-10.3</b>	<b>180.4</b>	<b>3.3</b>	<b>-123.7</b>	<b>308.2</b>	<b>-5.6</b>	<b>29.8</b>
<b>% of sales</b>	<b>-2%</b>	<b>37%</b>	<b>1%</b>	<b>-28%</b>	<b>61%</b>	<b>-1%</b>	<b>6%</b>
Amortizations	-53.4	-53.1	-57.7	-203.9	-65.6	-64.2	-64.5
<b>EBIT</b>	<b>-63.7</b>	<b>127.3</b>	<b>-54.4</b>	<b>-327.7</b>	<b>242.6</b>	<b>-69.8</b>	<b>-34.7</b>
<b>EBIT margin</b>	<b>-12%</b>	<b>26%</b>	<b>-12%</b>	<b>-75%</b>	<b>48%</b>	<b>-15%</b>	<b>-7%</b>
<b>EBITDA</b>	<b>3.5</b>	<b>193.2</b>	<b>13.3</b>	<b>-78.6</b>	<b>316.7</b>	<b>2.7</b>	<b>37.9</b>

## Revenues Trend by Business Line

<i>Amounts in SEK million</i>	<b>Q1-11</b>	<b>Q2-11</b>	<b>Q3-11</b>	<b>Q4-11</b>	<b>Q1-12</b>	<b>Q2-12</b>	<b>Q3-12</b>
<b>Core Products</b>							
Kineret	107.2	102.9	102.5	109.3	134.7	104.5	114.4
Orfadin	76.0	85.2	80.2	74.2	93.6	89.1	82.6
Other core products	17.2	18.7	19.0	19.8	21.8	22.8	17.7
<b>Total</b>	<b>200.4</b>	<b>206.8</b>	<b>201.7</b>	<b>203.3</b>	<b>250.1</b>	<b>216.4</b>	<b>214.7</b>
<b>Partner Products</b>							
Current portfolio	80.8	95.3	96.7	100.8	103.4	99.7	91.7
Discontinued products	22.5	17.1	5.4	0.0	0.0	0.0	0.0
Co-promotion revenues	28.3	26.2	24.5	26.0	12.0	0.0	0.0
<b>Total</b>	<b>131.6</b>	<b>138.5</b>	<b>126.6</b>	<b>126.8</b>	<b>115.4</b>	<b>99.7</b>	<b>91.7</b>
<b>ReFacto</b>							
Manufacturing revenues	166.4	108.5	98.9	77.9	116.9	107.5	118.9
Royalty revenues	38.9	36.3	19.7	28.3	24.2	44.0	38.5
<b>Total</b>	<b>205.3</b>	<b>144.8</b>	<b>118.6</b>	<b>106.2</b>	<b>141.1</b>	<b>151.5</b>	<b>157.4</b>
Other revenues	0.1	-0.3	0.1	0.0	0.0	13.1	0.0
<b>Total revenues</b>	<b>537.6</b>	<b>490.0</b>	<b>447.1</b>	<b>436.4</b>	<b>506.6</b>	<b>480.7</b>	<b>463.8</b>

**Profit and Loss Statement – Parent Company**

<i>Amounts in SEK million</i>	<b>Q3</b>		<b>Jan - Sep</b>		<b>Full year</b>
	<b>2012</b>	<b>2011</b>	<b>2012</b>	<b>2011</b>	<b>2011</b>
Total revenues	584.1	263.7	1,253.1	922.4	1,170.1
Total cost of goods and services sold	-239.9	-141.6	-612.7	-461.8	-647.2
<b>Gross profit</b>	<b>344.2</b>	<b>122.1</b>	<b>640.4</b>	<b>460.6</b>	<b>522.9</b>
Sales and Administration expenses <sup>1)</sup>	-111.0	-94.1	-320.6	-241.7	-380.1
Research and Development expenses <sup>2)</sup>	-96.5	-90.9	-290.7	-305.7	-534.7
Non recurring items	-34.0	–	-34.0	-20.9	-77.9
Other operating revenues/expenses	-8.9	-3.1	312.0	1.9	993.1
<b>Operating profit/loss</b>	<b>93.8</b>	<b>-66.0</b>	<b>307.1</b>	<b>-105.8</b>	<b>523.3</b>
Result from participation in Group companies	1.3	–	1.1	-0.2	-0.5
Financial income	3.8	9.1	23.9	11.8	11.1
Financial expenses	-13.2	-6.8	-28.5	-49.2	-65.0
<b>Profit/loss after financial items</b>	<b>85.7</b>	<b>-63.7</b>	<b>303.6</b>	<b>-143.4</b>	<b>468.8</b>
Income tax expenses	-33.1	–	-109.6	–	77.4
<b>Profit/loss for the period</b>	<b>52.6</b>	<b>-63.7</b>	<b>194.0</b>	<b>-143.4</b>	<b>546.2</b>
<b>Other comprehensive income</b>					
Cash flow hedge	-11.9	–	0.2	–	–
<b>Comprehensive income for the period</b>	<b>40.7</b>	<b>-63.7</b>	<b>194.2</b>	<b>-143.4</b>	<b>546.2</b>
<sup>1)</sup> Amortization and write-down of intangible assets included in Sales & Adm expenses	-13.6	-14.1	-40.9	-39.1	-62.9
<sup>2)</sup> Amortization and write-down of intangible assets included in Research and Development expenses	–	–	–	–	-127.6

**Balance Sheet – Parent Company**

<i>Amounts in SEK million</i>	Sep 30 2012	Jun 30 2012	Mar 31 2012	Dec 31 2011	Sep 30 2011
<b>ASSETS</b>					
<b>Fixed assets</b>					
Intangible fixed assets	633.2	643.5	651.8	665.9	799.1
Tangible fixed assets	130.7	137.3	135.1	143.5	207.0
Financial fixed assets	4,101.8	4,173.8	4,177.7	4,156.9	4,275.2
<b>Total fixed assets</b>	<b>4,865.7</b>	<b>4,954.6</b>	<b>4,964.6</b>	<b>4,966.3</b>	<b>5,281.3</b>
<b>Current assets</b>					
Inventories	671.1	766.5	657.3	716.8	799.5
Current receivables, non-interest bearing <sup>1)</sup>	1,343.9	1,306.9	1,460.0	1,101.7	471.0
Cash and cash equivalents	239.4	305.5	250.4	175.0	44.7
<b>Total current assets</b>	<b>2,254.4</b>	<b>2,378.9</b>	<b>2,367.7</b>	<b>1,993.5</b>	<b>1,315.2</b>
<b>Total assets</b>	<b>7,120.1</b>	<b>7,333.5</b>	<b>7,332.3</b>	<b>6,959.8</b>	<b>6,596.5</b>
<b>EQUITY AND LIABILITIES</b>					
<b>Shareholders' equity</b>	<b>5,776.3</b>	<b>5,732.6</b>	<b>5,725.1</b>	<b>5,530.0</b>	<b>4,832.3</b>
<b>Untaxed reserves</b>	<b>3.6</b>	<b>–</b>	<b>–</b>	<b>–</b>	<b>–</b>
<b>Long-term liabilities</b>					
Long-term debt	600.0	600.0	492.4	700.0	685.7
Long-term liabilities, non-interest bearing	19.5	19.0	19.0	–	–
<b>Total long-term liabilities</b>	<b>619.5</b>	<b>619.0</b>	<b>511.4</b>	<b>700.0</b>	<b>685.7</b>
<b>Current liabilities</b>					
Current liabilities, non-interest bearing	720.7	981.9	1,095.8	729.8	1,078.5
<b>Total short-term liabilities</b>	<b>720.7</b>	<b>981.9</b>	<b>1,095.8</b>	<b>729.8</b>	<b>1,078.5</b>
<b>Total equity and liabilities</b>	<b>7,120.1</b>	<b>7,333.5</b>	<b>7,332.3</b>	<b>6,959.8</b>	<b>6,596.5</b>

<sup>1)</sup> June includes a foreign exchange hedge of SEK 12 M.

**Change in Shareholder's Equity – Parent Company**

<i>Amounts in SEK million</i>	Jan - Sep		Full year
	2012	2011	2011
<b>Opening balance</b>	<b>5,530.0</b>	<b>4,375.9</b>	<b>4,375.9</b>
Sharebased compensation to employees	5.7	5.8	9.3
Issue of shares	–	594.0	594.0
Merger gain	46.4	–	–
Liquidation	–	–	4.5
Comprehensive income for the period	194.2	-143.4	546.2
<b>Equity, end of period</b>	<b>5,776.3</b>	<b>4,832.3</b>	<b>5,530.0</b>

## Notes

### Note 1 Accounting and valuation principles and other information

#### Important accounting principles

Swedish Orphan Biovitrum AB (publ) prepares its consolidated financial statements in accordance with the Annual Accounts Act, the Swedish Financial Reporting Board's recommendation RFR 1. Supplementary Accounting Rules for Groups, and the International Financial Reporting Standards (IFRS) and IFRIC interpretations as adopted by the EU. The consolidated financial statements have been prepared according to the historical cost convention except in the case of financial assets and financial assets and liabilities (including derivative instruments) measured at fair value in comprehensive income.

This interim report has been prepared in accordance with IAS 34, Interim Financial Reporting.

Accounting principles applied are in accordance with those described in the Annual Report 2011. Starting 1 January 2012, the group is no longer applying the "corridor method" in the current IAS 19, instead all actuarial gains and losses are recognized in other comprehensive income as incurred. Previous years' unrecognized actuarial losses, SEK 24.6 M, are reported as a change in accounting principle, directly against the opening balance of equity. More detailed information about the Group's accounting- and valuation principles can be found in the Annual Report 2011 which is available at [www.sobi.com](http://www.sobi.com).

#### Operating risks

All business operations involve risk. Managed risk-taking is necessary to maintain good profitability. Risk may be due to events in the external environment and may affect a certain industry or market. Risk may also be specific to a certain company. Swedish Orphan Biovitrum is exposed to three main risk categories:

- External risks such as patent infringements and competition within product concepts and decisions by authorities regarding product use and prices.
- Operational risk, e.g. the fact that developing a new drug is both capital-intensive and risky, dependence on external partners in various collaborations, product liability claims, as well as laws and rules on the treatment of hazardous materials
- Financial risks, such as currency risk, interest risk, credit risk and liquidity risk

A more detailed description of the Group's risk exposure and risk management is included in Swedish Orphan Biovitrum's 2011 Annual Report (see the Directors' Report).

### Note 2 Shares and Warrants

Development in share capital and number		No of shares	Share capital, SEK
<b>December 2011</b>		<b>267 295 132</b>	<b>146 664 000</b>
June 2012	Rights issue of class C shares	684 590	375 632
Sep 2012	Rights issue of class C shares	1 655 136	908 168
<b>Sept 2012</b>		<b>269 634 858</b>	<b>147 947 800</b>

A preferential new share issue of C shares was completed in September, 2012, after which the total number of shares is 269,634,858. The class C shares are intended to ensure fulfilment of commitments under the company's long-term incentive programs. Issued shares break down as 265,226,598 ordinary shares and 4,408,260 C shares. The ordinary shares carry one vote per share and the C shares carry 1/10 vote per shares. All C shares are treasury shares.

### **Option and share based incentive programs**

#### *Share based incentive program 2009*

The 2009 program expired on 9 June 2012. No shares were awarded under this program.

#### *Share based incentive program 2010*

A long-term, performance-based share program ("Share Program 2010") was adopted at the Annual General Meeting on 27 April 2010. Share Program 2010 covers management and key individuals in Swedish Orphan Biovitrum, and may involve a total maximum allocation of 429,925 shares in Swedish Orphan Biovitrum AB. The program is designed to allow the participant to invest in a number of shares and receive the equivalent number of shares free of charge if the individual stays with the company for three years. Employees also have the opportunity to receive additional shares based on Swedish Orphan Biovitrum's performance over a three-year benchmark period. The program was implemented in December 2010 and the benchmark period extends from 13 December 2010, through 12 December 2013.

#### *Share based incentive program 2011*

A long-term, performance-based share program ("Share Program 2011") was adopted at the Annual General Meeting on 28 April 2011. Share Program 2011 covers management and key individuals in Swedish Orphan Biovitrum, and may involve a total maximum allocation of 583,993 shares in Swedish Orphan Biovitrum AB. The program is designed to allow the participant to invest in a number of shares and receive the equivalent number of shares free of charge if the individual stays with the company for three years. Employees also have the opportunity to receive additional shares based on Swedish Orphan Biovitrum's performance over a three-year benchmark period. The program was implemented in December 2011 and the benchmark period extends from 15 December 2011, through 15 December 2014.

#### *Share based incentive program 2012*

A long-term, performance-based share program ("Executive program") was adopted at the Annual General Meeting on 26 April 2012. The Executive program covers management and key individuals in Swedish Orphan Biovitrum, and may involve a total maximum allocation of 670,800 shares in Swedish Orphan Biovitrum AB. The program is designed to allow the participant to invest in a number of shares and receive the equivalent number of shares free of charge if the individual stays with the company for three years. Employees also have the opportunity to receive additional shares based on Swedish Orphan Biovitrum's performance over a three-year benchmark period. The program was implemented in May 2012 and the benchmark period extends from 14 May 2012, through 14 May 2015.

A long-term, performance-based share program ("All Employee Program") was adopted at the Annual General Meeting on 26 April 2012. The all Employee Program covers permanent employees in Swedish Orphan Biovitrum, and may involve a total maximum allocation of 24,800 shares in Swedish Orphan Biovitrum AB. The program is designed so participants receive 100 shares free of charge if the performance criteria are met and if the individual stays with the company for three years. The program was implemented in May 2012 and the benchmark period extends from 14 May 2012, through 14 May 2015.

#### *Share program for CEO 2011*

The Extraordinary General Meeting held on 24 August 2011, adopted a performance based, long-term share program for the CEO Geoffrey McDonough (the "CEO Share Program 2011"). The program is based on an own investment in shares in the market, to be held during a three-year period, and the allotment of performance shares free of charge based on an increase in Swedish Orphan Biovitrum's share price during the performance period ending on 15 August 2014. For any allotment of performance shares to be possible, the share price at the end of the performance period shall amount to more than SEK 25.77. A maximum number of 500,000 performance shares can be allotted as follows:

#### **Pro-rata allotment of 400,000 performance shares**

If the share price at the end of the performance period amounts to at least SEK 45.00, 400,000 performance shares will be allotted. If the share price is between SEK 25.77 and SEK 45.00 at the end of the performance period, the portion of the 400,000 performance shares to be allotted shall be calculated on a pro-rata basis.

#### **Threshold allotment 1 of 30,000 performance shares**

In addition to the Pro-rata allotment, 30,000 performance shares will be allotted if the share price at the end of the performance period amounts to at least SEK 30.00

#### **Threshold allotment 2 of 70,000 performance shares**

In addition to the Pro-rata allotment and the Threshold allotment 1, 70,000 performance shares will be allotted if the share price at the end of the performance period amounts to at least SEK 35.00.

### **Note 3           Contingencies**

In 2004, the real estate designated as Paradiset 14 was transferred to a substantially foreign-owned limited liability partnership, called NyaParadisat KB, whereupon the participating interests in NyaParadisat KB were sold to an external party, at market price. The real estate was transferred to NyaParadisat KB, in accordance with the rules regarding so-called transfers below market value, in return for consideration equivalent to the real estate's value for tax purposes. In a submission to the county administrative court, dated 17 April 2008, the Swedish Tax Agency has formally requested that, pursuant the Swedish Tax Avoidance Act, the rules regarding transfers below market value shall not be applied. In the opinion of the Tax Agency, this entails that Swedish Orphan Biovitrum shall be charged a capital gain of SEK 234.5 M, as a consequence of the transfer of the real estate to NyaParadisat KB. In Swedish Orphan Biovitrum's view, it is patently obvious that the company has not acted in contravention of the purpose of the legislation, in the manner alleged by the Tax Agency in the aforementioned submission. Thereafter, on 9 October 2009, the Tax Agency lodged a new submission and, in reliance on two judgments from the Supreme Administrative Court dated 29 May 2009, has now alleged a new ground, as to why the rules governing transfers below market value shall not be applied by virtue of the Tax Avoidance Act. On 3 March 2011, the Administrative Court announced that they uphold the Tax Agency's request, explaining that Swedish Orphan Biovitrum under the tax law will be charged an amount of SEK 232.2 M as revenue in the 2005 tax year. The company has appealed to the Administrative Court of Appeal. The case was issued with a stay of proceedings in the Administrative Court of Appeal while awaiting the Supreme Administrative Court's (SAC) verdict on another separate tax avoidance issue, known as the Cyprus case, with certain similarities to Swedish Orphan Biovitrum's tax case. On 30 May 2012 SAC delivered its verdict in the Cyprus case. Although the verdict has similarities to Swedish Orphan Biovitrum's tax case, several key aspects are also different. Swedish Orphan Biovitrum is currently analyzing the verdict to assess how the Company's tax case may be affected. As there is no longer any ground for a stay of proceedings in the Administrative Court of Appeal, the case has been taken up for continued consideration and Swedish Orphan Biovitrum will have the opportunity to supplement and strengthen its legal submission.

On 29 March 2012, Swedish Orphan Biovitrum amended its share purchase agreement regarding the acquisition in 2005 of the pharmaceutical company Arexis AB. As stated in Swedish Orphan Biovitrum's annual and quarterly reports, the sellers of Arexis initiated arbitration as well as an expert determination procedure in 2011 regarding certain claims related to the share purchase agreement. Both proceedings have been withdrawn as a consequence of the amended share purchase agreement. According to the amended agreement, Swedish Orphan Biovitrum has no remaining development obligations towards the sellers. Under the amended agreement, Swedish Orphan Biovitrum will pay the sellers a total of SEK 77 M, of which SEK 43 M relates to the future milestone obligations for the Kiobrina program. Swedish Orphan Biovitrum has paid SEK 36 M in connection with the signing of the agreement and will pay SEK 20 M in 2013 and SEK 21 M in 2014.

-0-

### **Telephone Conference**

The interim report for the third quarter 2012 will be presented by CEO Geoffrey McDonough, COO Alan Raffensperger and CFO Annika Muskantor (Interim) at a media and analyst telephone conference.

**Time:** Tuesday, 30 October 2012 at 2 p.m. CET

#### **To participate in the telephone conference, please call:**

Sweden: +46 (0) 8 505 598 12

UK: +44 (0) 207 153 91 56

US: +1 866 676 58 69

A recorded version will be available afterwards at [www.sobi.com](http://www.sobi.com) under Investors & Media/Audio cast. Slides used in the presentation will also be available on the web site under Investors & Media/Presentations.

### **Financial calendar 2013**

Report for the fourth quarter and full year 2012	21 February
Interim Report, January-March, and AGM	26 April
Interim Report, January-June	18 July
Interim Report, January-September	30 October

*The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 30 October 2012 at 8.30 CET.*